Human proBNP peptide is a Synthetic blocking peptide. >95% and suitable for BL.
View Alternative Names
Natriuretic peptides B, Brain natriuretic factor prohormone, Gamma-brain natriuretic peptide, Iso-ANP, preproBNP, proBNP, NPPB
Reactivity data
You may be interested in:
Why is this recommended?
We recommend this product because it’s often used in the same experiment or related research.
We advise that you always check the datasheet to ensure it fits your experiments, or contact ourtechnical teamfor help.
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Specifications
Form
Lyophilized
General info
Function
Brain natriuretic peptide 32. Cardiac hormone that plays a key role in mediating cardio-renal homeostasis (PubMed : 1672777, PubMed : 17372040, PubMed : 1914098, PubMed : 9458824). May also function as a paracrine antifibrotic factor in the heart (By similarity). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins that drive various biological responses (PubMed : 1672777, PubMed : 17349887, PubMed : 17372040, PubMed : 21098034, PubMed : 25339504, PubMed : 9458824). Involved in regulating the extracellular fluid volume and maintaining the fluid-electrolyte balance through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion (PubMed : 1914098, PubMed : 9458824). Binds the clearance receptor NPR3 (PubMed : 16870210).. NT-proBNP. May affect cardio-renal homeostasis (PubMed : 17372040). Able to promote the production of cGMP although its potency is very low compared to brain natriuretic peptide 32 (PubMed : 17372040).. BNP(3-32). May have a role in cardio-renal homeostasis (PubMed : 17372040). Able to promote the production of cGMP (PubMed : 17372040).
Sequence similarities
Belongs to the natriuretic peptide family.
Post-translational modifications
The precursor molecule is proteolytically cleaved by the endoproteases FURIN or CORIN at Arg-102 to produce brain natriuretic peptide 32 and NT-proBNP (PubMed:10880574, PubMed:20489134, PubMed:21314817, PubMed:21482747, PubMed:21763278). This likely occurs after it has been secreted into the blood, either during circulation or in the target cells (PubMed:21482747). CORIN also cleaves the precursor molecule at additional residues including Arg-99 and possibly Lys-105 (PubMed:20489134, PubMed:21763278). In patients with heart failure, processing and degradation of natriuretic peptides B occurs but is delayed, possibly due to a decrease in enzyme level or activity of CORIN and DPP4 (PubMed:25339504).. Brain natriuretic peptide 32. Undergoes further proteolytic cleavage by various proteases such as DPP4, MME and possibly FAP, to give rise to a variety of shorter peptides (PubMed:16254193, PubMed:19808300, PubMed:21098034, PubMed:21314817). Cleaved at Pro-104 by the prolyl endopeptidase FAP (seprase) activity (in vitro) (PubMed:21314817). Degraded by IDE (PubMed:21098034). During IDE degradation, the resulting products initially increase the activation of NPR1 and can also stimulate NPR2 to produce cGMP before the fragments are completely degraded and inactivated by IDE (in vitro) (PubMed:21098034).. O-glycosylated on at least seven residues (PubMed:16750161, PubMed:17349887, PubMed:20489134, PubMed:21482747, PubMed:21763278). In cardiomyocytes, glycosylation at Thr-97 is essential for the stability and processing of the extracellular natriuretic peptides B (PubMed:21482747). Glycosylation, especially at Thr-97, may also be important for brain natriuretic peptide 32 stability and/or extracellular distribution (PubMed:21763278). Glycosylation at Thr-97 appears to inhibit FURIN- or CORIN-mediated proteolytic processing, at least in HEK293 cells (PubMed:20489134, PubMed:21763278).
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com